Nasal Spray Restores Memory and Reverses Brain Aging in Preclinical Study

Recent preclinical research suggests that intranasal delivery systems may offer a potent method for treating neurodegenerative conditions and brain injuries by bypassing the blood-brain barrier to deliver medicine directly to the brain.

One specific area of development involves a nasal spray designed to target neuroinflammation. In a study led by researchers at Mass General Brigham, the monoclonal antibody Foralumab, produced by Tiziana, was tested in mouse models of traumatic brain injury (TBI). The study, published in Nature Neuroscience, found that the nasal anti-CD3 spray could reduce damage to the central nervous system and mitigate behavioral deficits.

Mechanism of Action in Brain Injury

The research indicates that the nasal anti-CD3 spray works by inducing regulatory immune cells to travel to the brain. Once there, these cells interact with microglial cells to control the inflammatory response.

This mechanism is particularly significant because chronic inflammation is identified as a primary reason for the long-term effects of traumatic brain injury, including cognitive decline and disability. According to Saef Izzy, MD, FNCS, FAAN, a neurologist and head of the Immunology of Brain Injury Program at Brigham and Women’s Hospital, there is currently no treatment to prevent these long-term effects.

Applications for Alzheimer’s and Aging

While the Mass General Brigham study focused on TBI, the nasal spray being tested—Foralumab—has also been evaluated in clinical trials for patients with Alzheimer’s disease and multiple sclerosis.

Other research into intranasal delivery focuses on the aging brain. Some preclinical models have demonstrated that nasal sprays can restore memory and reverse inflammation. Researchers have explored the use of nano-sized vesicles derived from neural stem cells delivered via nasal spray to reduce brain inflammation and plaque while preserving cognition.

The potential for nasal sprays to revolutionize Alzheimer’s treatment lies in their ability to swiftly deliver brain-boosting medicine to improve cognitive function.

Broader Neuroprotective Research

Beyond monoclonal antibodies, other compounds are being screened for intranasal delivery to treat brain injuries. A February 16, 2024, study published in the Journal of Translational Medicine discussed the delivery of mitochondria-targeted neuroprotective compounds for TBI.

This research includes the study of a nasal spray containing N-acetylcysteine (NAC), which has shown efficacy in restoring brain energy supplements and reversing the pathogenesis of traumatic brain injury.

Current Status and Limitations

much of this evidence is derived from preclinical models, such as mouse models, rather than human clinical trials. While the results show promise for reducing neuroinflammation and restoring memory, these findings must be validated in human subjects before they can be established as standard medical treatments.

The transition from preclinical success to clinical application involves ongoing testing of antibodies like Foralumab to determine if the results observed in animal models translate to the prevention of cognitive decline and the treatment of acute brain injuries in humans.